Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Ondine Biomedical, Inc. ( (GB:OBI) ) is now available.
Ondine Biomedical Inc. has announced the grant of 500,000 options to its non-executive directors and the issuance of 1,450,000 warrants to key vendors. The directors’ options vest over four years with an exercise price of 12 pence, reflecting the company’s share price at the time of approval. The warrants, including 250,000 issued to a former board member now involved in a Phase 3 clinical trial, have a strike price of 17 pence and expire in December 2025. These financial instruments are part of Ondine’s strategy to incentivize its leadership and partners, supporting its ongoing product development and clinical trials, which could enhance its market position in the life sciences sector.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies, also known as photodisinfection. The company has a pipeline of investigational products utilizing its proprietary photodisinfection technology, with its nasal photodisinfection system having received a CE mark in Europe and approvals in Canada and other countries under the name Steriwave®. Ondine’s products target medical indications such as chronic sinusitis and ventilator-associated pneumonia, and the company is conducting clinical trials in the US for regulatory approval.
YTD Price Performance: 37.14%
Average Trading Volume: 527,854
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £51.51M
See more data about OBI stock on TipRanks’ Stock Analysis page.
